🔗 Share this article

While America proceeds with historic changes to its immunization schedules, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by questioning COVID-19 shots during the pandemic and has zeroed in on possible fatalities following Covid immunization in her short position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Schedule

Health officials were set to unveil radical revisions to the pediatric vaccine schedule recently, bringing the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of alignment with much of the global community with no evidence for public health gain. The announcement has been pushed back until the new year.

In place of Vinay Prasad, Dr. Høeg is set to address the audience at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the office this year.

A New Direction at the FDA

Høeg's temporary position may indicate a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has often pushed for ending certain childhood vaccine recommendations in the US so as to align more in line with the Danish model, a country with nationalized medicine and a citizenry about the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on immunizations – usually the domain of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Questions Over Qualifications

Høeg has no apparent background in medication creation, regulation or leadership, which has been typical for previous leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She has no expertise in running a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who headed the center have had.”

The drug center has an enormous portfolio at the agency, the former commissioner emphasized.

“The public just focuses on the innovative therapies, but the generic program authorizes thousands of generic medications. There’s a biosimilars program, over-the-counter program and more, and every single one have to be managed,” Dr. Woodcock explained. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative element to the role, which manages more than 5,000 staff members. “It’s a huge leadership role, if you do it right,” Woodcock said.

Response and Controversial Programs

Regarding questions about Høeg’s credentials and whether this selection indicates increased cooperation among agency officials on immunizations, a representative stated that the “concerns are based on incorrect presumptions”.

“Her experience matches the responsibilities of her job,” the spokesperson explained, citing the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed rapid drug-approval program that reportedly worried her former heads. “How are these drugs being selected for this voucher program? Who makes the choices?” Dr. Howard said. “There’s a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards laxer oversight of all drugs, with the exception of vaccines.”

Public Track Record on Vaccines

With immunizations, Høeg has a more established, if concerning, past, critics observe. She authored a study using unverified crowd-sourced reports to determine the frequency of myocarditis after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccines are riskier than they are.

Included in her “policy goals” for the current government featured changing regulations for recently developed shots and halting “non-essential” vaccines, she remarked following the vote on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of preventing adolescent males from obtaining Covid vaccines.

“She is an complete ideologue who begins with her beliefs and tailors the evidence to retrofit the evidence in a very misleading, dishonest way,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|